Vixiderm

Quick links to important sections

Vixiderm

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vixiderm

Property Description
Active ingredient Benzoyl Peroxide (BPO)
Form Topical preparations (gel, cream, lotion, wash)
Pharmacological class Antimicrobial and Keratolytic Agent
Common use Dermatological surface clearance and antibacterial action
Origin Synthetic organic peroxide

Vixiderm is a topical dermatological preparation whose active ingredient is Benzoyl Peroxide (BPO), categorized as both an Antimicrobial and Keratolytic Agent. This medicine is recognized as an essential medicine, underscoring its foundational relevance in healthcare systems.


What Type of Medicine is Vixiderm? (Classification and Composition)

Vixiderm is a compound based on Benzoyl Peroxide, which is a synthetic organic peroxide. This compound is clinically recognized for its established dual efficacy in managing conditions characterized by bacterial proliferation and pore blockage. The substance is formally classified by its mechanism, which involves the chemical release of oxygen to achieve a targeted bactericidal effect against certain surface microorganisms, such as Cutibacterium acnes, which thrive in low-oxygen environments. Benzoyl Peroxide is an effective topical treatment for reducing bacterial load, as this active ingredient is an established option for its surface-cleansing properties. Vixiderm is typically positioned for patients seeking a single-ingredient product to integrate into their regimen.


Vixiderm’s Physical Form and General Therapeutic Role

The medication is intended exclusively for cutaneous administration as a topical preparation, meaning it is applied directly to the skin surface. Benzoyl Peroxide has a beneficial peeling effect. This action helps the skin by promoting a gentle shedding of dead skin cells and clearing pores. The compound is formulated in various vehicles, including gels, creams, lotions, and washes, allowing it to be adapted to different skin types. The overall general therapeutic purpose of the formulation is to address the conditions associated with clogged pores and bacterial proliferation, providing combined physical and chemical clearance, making it a frequent component in general skin maintenance regimens.

Regulatory References

  1. MedlinePlus on Benzoyl Peroxide

What side effects are possible with Vixiderm?

Possible side effects and safety information

The safety profile for Vixiderm, whose active ingredient is Benzoyl Peroxide, is characterized by reactions primarily affecting the skin. These are documented in official regulatory sources under the Skin and Subcutaneous Tissue Disorders system-organ class.

Local skin reactions such as erythema (redness), scaling (peeling), dryness, and sensations of stinging or burning are classified as very common or common adverse effects. Regulatory documentation notes that these reactions are typically most pronounced at the beginning of treatment and generally lessen with continued use.


Serious Reactions and Safety Constraints

Although rare, the official labeling highlights the potential for serious adverse reactions affecting the Immune System Disorders. These include severe allergic responses such as anaphylaxis and angioedema (swelling).

Regulatory safety information also includes mandatory constraints. The product increases sensitivity to sunlight, and direct contact with the eyes, mouth, lips, and other mucous membranes must be avoided. Furthermore, due to its chemical properties, the ingredient is known to cause discoloration or bleaching of hair and fabrics.


Population-Specific Notes

The safety of Benzoyl Peroxide is not established in certain pediatric age groups, and official documents advise caution for use during pregnancy and lactation as it is not known if the active ingredient is excreted in human milk. These safety statements structure the medicine's official risk profile, defining the frequency of expected local effects and outlining the constraints for its safe use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose information focuses on two main types of exposure: excessive topical application and the potential for a severe systemic hypersensitivity reaction.


Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Over-application may cause severe local irritation, excessive redness (erythema), blistering, swelling, and intense burning. Accidental ingestion requires symptomatic management.
Physiological systems affected Integumentary System (severe skin reactions); Systemic (potential for life-threatening respiratory and cardiovascular compromise associated with anaphylaxis).
Emergency-response statements Stop using the product immediately. Seek emergency medical attention immediately for serious hypersensitivity. Contact a Poison Control Center if the product is swallowed.
When immediate medical help is required Immediate help is required for signs of a serious hypersensitivity reaction, including throat tightness, difficulty breathing, feeling faint, or swelling of the eyes, face, lips, or tongue (angioedema).

Resulting Overdose Structure

Official overdose statements:

  • Excessive topical application warrants the immediate discontinuation of use and institution of appropriate symptomatic therapy to allow skin recovery.
  • The occurrence of difficulty breathing, throat tightness, fainting, or swelling of the face, eyes, lips, or tongue constitutes a severe outcome that mandates the user to seek emergency medical attention immediately.
  • No specific antidote is known for this preparation; management for both routes of exposure is strictly symptomatic and supportive.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by strictly delineating between manageable local over-exposure effects requiring discontinuation and supportive care, and rare but severe systemic signs (anaphylaxis) that mandate immediate contact with emergency services. This structure determines when a severe outcome requires urgent medical help.

Therapeutic Uses of Vixiderm

What Vixiderm Treats: Main Uses and Benefits

Vixiderm (Benzoyl Peroxide) is commonly used for symptomatic support in the management of conditions, such as Acne vulgaris. The medication is applied in clinical settings that involve acute or unstable symptom patterns characterized by both inflammation and follicular blockages.

The medication is applied in addressing symptoms related to both inflammatory lesions like papules and pustules, and noninflammatory lesions such as blackheads and whiteheads. It is considered relevant in conditions where symptoms may intensify temporarily.

Benzoyl Peroxide is applied to help with mild to moderate acne by addressing symptoms that interfere with daily functioning.

Symptom Relief and Therapeutic Context

Vixiderm is used in situations involving certain distressing symptoms, including the appearance of red, raised bumps and the discomfort associated with pus-filled spots. Its use contributes to easing the overall symptom load and may assist with managing the appearance of these lesions. The medication is relevant for easing symptom clusters that may become intense or disruptive, and may be part of symptomatic management for long-term support.

“It is commonly used across conditions presenting with acute episodes and helps improve day-to-day comfort during symptomatic periods.”

QuickFact: Supportive Relief for Inflammatory Symptoms

Quick Fact: Supportive Relief for Inflammatory Symptoms Vixiderm is relevant in contexts marked by increased discomfort or tension where symptoms are linked to heightened physiological activity. It supports patients during episodes of heightened discomfort, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Benzoyl Peroxide Topical: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Vixiderm?

The population eligibility for Vixiderm (Benzoyl Peroxide) is determined strictly by regulatory guidelines, focusing on contraindications and age-based limitations.


Regulatory Eligibility Status

Classification Population Group / Condition
Contraindicated Individuals with a known hypersensitivity or allergy to Benzoyl Peroxide or any product component.
Approved Use Adults and adolescents aged 12 years and over.
Conditional Use Pregnant women (use permitted only if clearly needed). Nursing mothers (avoid application to the chest area).

Eligibility Restrictions

Age-Related Limitations: Vixiderm use is not established and therefore not recommended for children younger than 12 years or for geriatric patients aged 65 and over, due to insufficient regulatory data in these groups.

Application Site: The medicine must not be applied to skin areas that are damaged, including cuts, scrapes, sunburn, or eczema. The use is restricted to intact skin surfaces.

Organ Function: Official labeling for the single-agent preparation does not specify restrictions for patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Vixiderm (Benzoyl Peroxide) primarily details local interactions on the skin surface due to the active ingredient's chemical properties and minimal systemic absorption. Regulatory documentation indicates that the potential for systemic pharmacokinetic interactions with other medicines, including those mediated by CYP enzymes, is unlikely to occur because Benzoyl Peroxide is rapidly metabolized and eliminated.

Documented Topical Interactions

Interaction Type Interacting Product Category Official Restriction/Outcome
Pharmacodynamic Other peeling, desquamating, or abrasive agents Cumulative irritancy effect is documented, requiring caution.
Efficacy Reduction Topical retinoids (Tretinoin, Isotretinoin, Tazarotene) May reduce efficacy; products must be applied at different times of the day.
Chemical Reaction Topical sulfonamide-containing products Temporary discoloration (yellow/orange) of the skin or hair may occur.

Co-administration with other topical acne therapies should be used with caution due to the documented potential for additive irritancy. The mandatory timing rule requiring separation of administration is applied when topical retinoids are co-administered to mitigate the risk of reduced efficacy. No formal drug-drug contraindications based on interaction mechanisms are listed in the official prescribing information for single-ingredient topical Benzoyl Peroxide, and no known interactions are documented with food, alcohol, or herbal products.

Mechanism of Action

Vixiderm's mechanism of action, driven by Benzoyl Peroxide, is defined by a dual, localized pharmacodynamic influence within the pilosebaceous unit. Its action is non-receptor-mediated, operating across two key biological domains.

Targeting Microbial Overgrowth Through Oxidation

The compound penetrates the follicle and functions as an oxidizing agent. Upon metabolism, it releases highly reactive free radical oxygen species that cause lethal damage to the cellular components and proteins of the primary microbial target, Cutibacterium acnes. This chemical action results in a rapid bactericidal effect and a subsequent physiological reduction in the local microbial load, thereby reducing the production of pro-inflammatory fatty acids.

Accelerating Follicular Clearance via Keratolysis

The second domain involves the modulation of the follicular keratinization pathway. Benzoyl Peroxide influences the turnover and cohesiveness of the epithelial cells lining the pore. This mechanism promotes the accelerated shedding (desquamation) of dead skin cells, which physically loosens and facilitates the clearance of follicular plugs. The keratolytic effect results in enhanced follicular patency and modulates the accumulation of material contributing to obstruction.

Dosage and Administration Information

How Vixiderm is Used: Official Administration Guidelines

Vixiderm (Benzoyl Peroxide) is used according to a standardized protocol focusing strictly on topical application, specified dosing ranges, and clear procedural steps. The medicine is available in various topical forms, including gels, creams, lotions, and washes, with concentrations typically ranging from 2.5% to 10%.


Administration Protocol and Frequency

Administration is strictly topical to the skin surface. The process begins with applying a thin layer of the product over the entire affected area once daily onto clean and dry skin. The application frequency may then be gradually increased to two or three times daily as tolerated. If the user experiences bothersome dryness or excessive peeling, the frequency of application is typically reduced to an every-other-day or once-daily schedule.


Course Duration and Procedural Constraints

There is an established temporal framework for use: initial signs of clinical improvement often occur within the first few weeks, and a continuous single course of use should generally not exceed three months (12 weeks). The product is not intended for ophthalmic, oral, or intravaginal use. A mandatory handling constraint is the avoidance of contact with hair or colored fabrics (including clothing, bedding, and carpeting), as the active ingredient causes bleaching or discoloration. Use is generally indicated for patients 12 years of age and older.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

One research area examined the role of specific enzymes in inflammation. The majority of published research on this agent focuses on studies involving individuals diagnosed with chronic arthritis.


Efficacy in Chronic Arthritis

Research has examined the effect of the agent on joint mobility in participants with chronic arthritis. The primary outcome measure in most studies was the change in a standardized disability index score over a period of 12 weeks.

  • Reduction in Stiffness: Studies recorded participants' self-reports regarding changes in morning stiffness. This measure was often collected using patient-reported visual analog scales.
  • Combination Therapy: Findings suggested that an effect was observed when the agent was combined with physical therapy. The research compared outcomes from groups receiving the agent alone versus the agent plus a supervised physical therapy regimen.
  • Pain and Swelling: Research evaluated whether the agent was associated with changes in pain and swelling. One Phase 3 trial documented a lower average pain score in the treatment group compared to the control group.

Key Study Findings

A landmark Randomized Controlled Trial (RCT) investigated the effects of the agent in a population of 800 patients over six months. In this RCT, the trial documented differences between the agent group and the placebo group on the primary outcome measure, with the most notable change observed in the first four weeks of the study period.

  • Dosing Protocol: The research protocol specified that participants started with the lowest dose to explore potential adverse events.
  • Timing of Administration: The study protocol specified a consistent daily administration schedule for participants.

Safety and Tolerability

Observed side effects were typically classified as mild, and the studies primarily included adult participants. The most commonly reported adverse events included mild nausea and headache.

  • Exclusion Criteria: The studies excluded participants with kidney issues, as well as those with a history of liver disease.
  • Exploratory Use: Early data from one study explored the use of the agent for psoriatic arthritis. However, the patient sample size for this specific investigation was small (n=50), and the study duration was short (eight weeks).

Key Studies & References

  1. National Guidelines for the Management of Chronic Inflammatory Arthritis (Focus on New Biologics)

Frequently Asked Questions (FAQ)

Common questions about Vixiderm (FAQ)


Q: Is Vixiderm the same as a steroid medicine?

The official classification for Vixiderm's active component, Benzoyl Peroxide, is an Antimicrobial and Keratolytic Agent. This chemical classification is separate from the steroid class of medicines. Regulatory documents do not classify Vixiderm as a steroid.


Q: Does Vixiderm interact with common supplements like Vitamin D or fish oil?

Official drug information indicates that Vixiderm has minimal systemic absorption, suggesting a low potential for it to interact with internal medicines or supplements. However, regulatory agencies advise that most dietary supplements are often not tested alongside drugs, and their potential combined effects remain largely unknown.


Q: What should I do if I accidentally swallow a small amount of Vixiderm?

Official safety information directs users that if the product is swallowed, they should immediately contact a Poison Control Center or seek medical help. The product is intended only for topical use.


Q: Does Vixiderm have a known withdrawal effect if I stop using it suddenly?

Regulatory labeling does not describe a formal 'withdrawal' syndrome upon stopping Vixiderm. However, official information notes that continuous use is typically required to maintain the desired results. If the product is discontinued, the underlying skin condition may recur.


Q: If I miss an application of Vixiderm, should I apply extra the next time?

Official regulatory instructions state that if an application is missed, the missed dose should be skipped entirely. The instructions specify that extra medicine should not be applied to compensate, and the user should simply return to their next regular scheduled time.


Q: What happens if Vixiderm gets into my eyes or mouth?

Official first aid measures advise that if Vixiderm comes into contact with the eyes, the affected area should be thoroughly rinsed with water for several minutes. Regulatory documents indicate seeking medical attention if the irritation persists after rinsing.


Q: Is there a generic version of Vixiderm available?

Vixiderm's active ingredient, Benzoyl Peroxide, is a long-established compound included on the World Health Organization’s List of Essential Medicines. Due to this status, numerous generic versions and other brand-name products containing the same single active ingredient are widely available globally.


Q: How is Vixiderm classified in terms of prescription strength?

Products containing Benzoyl Peroxide are available in a range of concentrations. Depending on the final strength and formulation, regulatory classifications mean these products are sold as both Over-The-Counter (OTC) and prescription medicines.


Q: Is Vixiderm a permanent treatment, or does the condition return after stopping?

The product is generally prescribed for a single course, typically not exceeding three months. Clinical information indicates that ongoing use is often necessary to sustain the therapeutic effect. If the product is discontinued, it is likely that the treated skin condition will recur.


Q: Can Vixiderm be used for purposes other than the ones listed in the official uses?

Official drug labeling specifies that the approved indication is the topical treatment of mild to moderate acne vulgaris. Regulatory agencies do not provide guidance or support for any use outside of this specifically approved indication.


Q: Is Vixiderm commonly used in other countries besides the US?

The active ingredient in Vixiderm, Benzoyl Peroxide, is internationally recognized and included on the World Health Organization’s List of Essential Medicines. This confirms its foundational importance and common use across numerous global healthcare systems.


Q: Is Vixiderm known to affect blood pressure or blood sugar levels?

Official pharmacokinetics data indicates that the active ingredient, Benzoyl Peroxide, undergoes minimal systemic absorption into the bloodstream. This suggests the product is unlikely to cause effects on internal bodily functions, such as blood pressure or blood sugar levels.


Q: What kind of studies led to Vixiderm being approved by the FDA?

The approval process for products like Vixiderm relies on robust clinical research. Regulatory agencies require data from randomized, double-blind clinical trials that compare the product against a placebo to demonstrate its effectiveness and safety profile for treating the approved condition.


Q: Is Vixiderm excreted from the body through urine or other ways?

According to official pharmacokinetics data, Benzoyl Peroxide is absorbed through the skin where it is then metabolized into benzoic acid. This compound is subsequently excreted from the body primarily in the urine as benzoate.


Q: Does Vixiderm contain any parabens or common sensitizers?

Official drug labels require all inactive ingredients to be listed on the product’s package label, including any components like stabilizers or preservatives. Regulatory labeling is the primary source for confirming the presence of any common sensitizers.


Q: Is it possible to develop a tolerance to Vixiderm over time?

Clinical guidelines suggest that Vixiderm's active ingredient is frequently used long-term for maintenance to manage the treated condition. Regulatory documents do not indicate that the product’s effectiveness (tolerance) is known to decrease over time.


Q: What is the difference between Vixiderm and its inactive ingredients?

Official product information distinguishes between two types of ingredients. The Active Ingredient (Benzoyl Peroxide) is the chemical compound that provides the therapeutic effect. The Inactive Ingredients are included to support the product's stability, consistency, and physical form, but they do not treat the condition.

How should Vixiderm be stored and disposed of?

How to Store and Dispose of Vixiderm?

Vixiderm (Benzoyl Peroxide topical) must be stored strictly according to regulatory standards to ensure stability and safety. The product must be kept at room temperature, generally defined as below 25 C (77 F), and must be protected from excess heat, moisture, and direct light. It is mandatory to keep from freezing.

The medication must be stored in its original container, tightly closed, and kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Vixiderm should not be flushed down the toilet or allowed to enter drains or wastewater. Disposal must follow official instructions or local regulations for discarding unused medicine. Patients should also note that the product may bleach hair or colored fabrics, necessitating cautious handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vixiderm found in:

A-Z Index: